NetScientific PLC Vortex Releases Publication in Nature Scientific
February 09 2018 - 1:00AM
RNS Non-Regulatory
TIDMNSCI
NetScientific PLC
09 February 2018
Publication in Nature Scientific Reports Describes Potential of
Vortex Technology in Personalised Medicine for Lung Cancer
patients
London, UK - 09 February 2018 - NetScientific plc
("NetScientific", AIM:NSCI), the transatlantic healthcare IP
commercialisation group, notes that its portfolio company, Vortex
BioSciences, has announced a report published by Nature Scientific
Reports. The peer reviewed report, titled "Evaluation of PD-L1
expression on vortex-isolated circulating tumor cells in metastatic
lung cancer" describes the use of the Vortex's technology in
capturing circulating tumour cells (CTCs), in combination with the
use of a novel immunofluorescence assay, for measuring programmed
cell death ligand 1 (PD-L1) expression on the surface of the CTCs
from patients with metastatic non-small cell lung cancer
(NSCLC).
The report can be found online here:
https://www.nature.com/articles/s41598-018-19245-w
Commenting on the news, Francois Martelet, Chairman of Vortex
BioSciences Inc. and CEO of NetScientific said: "This report
demonstrates the potential clinical utility of circulating tumour
cells captured by the Vortex technology in the treatment of lung
cancer patients. Recent clinical trials of PD-1 and PD-L1
inhibitors have returned promising clinical responses, providing a
rationale for use of the VTX 1 system in personalised
medicine."
# # #
For more information, please contact:
NetScientific Tel: +44 (0)20 3514 1800
François R. Martelet,
M.D., CEO
Ian Postlethwaite,
CFO
Consilium Strategic
Communications Tel: +44 (0)20 3709 5700
Mary-Jane Elliott / netscientific@consilium-comms.com
Jessica Hodgson /
Chris Welsh / Laura
Thornton
Stifel Nicolaus Europe
Limited (NOMAD and Broker) Tel: +44 (0) 20 7710 7600
Jonathan Senior / David
Arch / Ben Maddison
Vortex Biosciences Tel: +1 (0) 415 823 7649
Steve Crouse steve@vortexbiosciences.com
About NetScientific
NetScientific is a transatlantic healthcare technology group
with an investment strategy focused on sourcing, funding and
commercialising technologies that significantly improve the health
and well-being of people with chronic diseases. For more
information, please visit the website at www.netscientific.net
MEDIA CONTACT
Steve Crouse
415-823-7649
steve@vortexbiosciences.com
Vortex Biosciences Announces Publication in Nature Scientific
Reports Describing the Measurement of PD-L1 Expression on
Circulating Tumor Cells
CTC PD-L1 Expression Could Supplement Tissue PD-L1 Measurements
to Aid in Patient Selection and Cancer Status Monitoring for
Immunotherapy Treatments
MENLO PARK, CA, February 8, 2018 - Vortex Biosciences, provider
of circulating tumor cell (CTC) capture systems, today announced
the publication of "Evaluation of PD-L1 expression on
vortex-isolated circulating tumor cells in metastatic lung cancer"
in Nature Scientific Reports on February 7(th) . The peer reviewed
publication describes the use of the Vortex technology to capture
CTCs and a novel immunofluorescence assay for measuring programmed
cell death ligand 1 (PD-L1) expression on the surface of the CTCs.
Reasonable correlation between the PD-L1 expression on the CTCs and
on paired tissue biopsy samples was observed, suggesting that CTCs
may offer a way to monitor PD-L1 status on tumor cells over the
course of a patient treatment from simple non-invasive blood
draws.
Overexpression of PD-L1 has been identified as a pathway that
metastatic tumor cells use to evade immune detection. PD-L1 binds
to PD-1 on T-cells and suppresses their activity. Immunotherapy
based on inhibition of PD-1 or PD-L1 represents a breakthrough in
the treatment of advanced cancers. Today, solid tumor patients are
screened for PD-L1 expression on their tumor cells following a
tissue biopsy. PD-L1 expression levels have been demonstrated to be
a reasonable biomarker for stratifying patients that will respond
better to immunotherapy treatments.
Utilizing biopsies for this patient stratification does have its
limitations. Specifically, tumor biopsies are risky, expensive and
cannot be performed serially to understand cancer status throughout
the course of a treatment. Measuring PD-L1 expression on CTCs
through a simple blood draw enables a low cost, low risk approach
to initial patient stratification and presents an opportunity to
monitor PD-L1 expression on patient tumor cells over the course of
the disease.
"PD-L1 is a critical biomarker for identifying patients that can
respond better to immunotherapy," said Gene Walther, Chief
Executive Officer of Vortex Biosciences. "PD-L1 expression analysis
can now be performed on CTCs isolated by the VTX-1 system, opening
up the potential to improve the understanding of how the expression
levels are changing on tumor cells throughout a patient's disease
and improve treatment."
The fully automated VTX-1 Liquid Biopsy System from Vortex
represents the next step in CTC isolation. With a cancer cell
recovery of >60%, best in class CTC purity, and collected CTCs
being intact, viable, and ready for downstream analysis, the VTX-1
offers the best CTC samples available today. The VTX-1 utilizes a
proprietary microfluidic chip to stably trap and capture CTCs in
micro-scale vortices based on their larger size and greater
deformability than the white and red blood cells. The isolated CTCs
can then be analyzed by a wide range of analytical techniques
including next gen sequencing (NGS), polymerase chain reaction
(PCR), fluorescent in-situ hybridization (FISH), and immunostaining
enabling CTCs to become the basis for diagnostic decisions.
About Vortex Biosciences
Vortex Biosciences is a cancer research and diagnostics company
that integrates cancer biology, microfluidic engineering and
informatics to develop tools for isolating and characterizing
circulating tumor cells. The Vortex VTX-1 instrument harvests
intact circulating tumor cells from whole blood samples for use in
downstream research and clinical applications such as patient
stratification in clinical trials, monitoring disease progression
and drug treatment effectiveness. With a mission to enable
noninvasive diagnosis of cancer and real-time monitoring throughout
a patient's treatment, Vortex is at the forefront of accelerating
cancer research and improving patient outcomes. Vortex is a core
subsidiary of NetScientific plc, a transatlantic healthcare
technology group with an investment strategy focused on sourcing,
funding and commercializing technologies that significantly improve
the health and well-being of people with chronic diseases. For more
information, visit www.vortexbiosciences.com.
# # #
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRALVLLBVLFBBBE
(END) Dow Jones Newswires
February 09, 2018 02:00 ET (07:00 GMT)
Netscientific (LSE:NSCI)
Historical Stock Chart
From Apr 2024 to May 2024
Netscientific (LSE:NSCI)
Historical Stock Chart
From May 2023 to May 2024